On October 31, Professor Li Liangping, chairman and founder of Tesai Immunization (Guangzhou) Technology Co., Ltd. and his team visited Shenzhen Cell Valley for exchange. Wang Jianxun, chief scientist of Shenzhen Cell Valley, Tang Xiaomeng, deputy general manager, Sun Rui, Director of Marketing Department, and Wu Xiaosheng, director of Sales Department, warmly received and held discussions and exchanges to discuss the direction of cooperation and specific matters.

First of all, under the leadership of Minister Sun Rui, the Tesai Immune team visited the smart exhibition hall, GMP level production workshop and R&D laboratory of Shenzhen Cell Valley, and initially understood the development history, strategic layout and complete production and R&D pipeline of Shenzhen Cell Valley.

At the symposium, Minister Sun Rui introduced the advantages of products and services, core technology - retroviral vector, cooperation cases and the comprehensive strength of the enterprise to the Tesai Immunization team in detail. Subsequently, Professor Li Liangping and Professor Wang Jianxun had in-depth communication on the development status of cellular immunotherapy, recent research results, TCR-T therapy, and industrial application of retroviral vectors. The two sides have reached a high degree of consensus on the advantages of large retroviral vector packaging capacity and low industrialization cost, and plan to replace the underlying technology of TCR-T existing R&D pipeline with retroviral vector, and carry out comprehensive cooperation in the direction of IIT clinical research and new drug application, so as to deepen the research and development of TCR-T cell therapy. Jointly promote the progress and development of cell and gene therapy.

Professor Li Liangping highly recognized the technical team and strategic layout of Shenzhen Cell Valley. Shenzhen Cell Valley has the first R&D and production team that has mastered the industrial retrovirus vector technology (PackRV-SS system) in China, and the retrovirus vector has the advantages of high transfection efficiency and stable expression effect compared with other vectors. It is hoped that through the core technology of Shenzhen Cell Valley - efficient and stable retroviral vector, TCRT research and clinical application can be promoted to a new height.

Through this exchange visit, the two sides have laid a good foundation for jointly promoting the research and development of TCR-T cell therapy, and have made positive contributions to truly benefiting the majority of cancer patients.